← All trials
NCT02811263
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2017
- Primary completion
- Jun 1, 2022
- Completion date
- Sep 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- University of California, San FranciscoReponsible party - principal investigator
- University of North Carolina at Chapel HillCollaborator
- University of WashingtonCollaborator
- Mednax Center for Research, Education and QualityCollaborator
- University of UtahCollaborator
- Indiana UniversityCollaborator
- Stanford UniversityCollaborator
- University of PittsburghCollaborator
- Boston UniversityCollaborator
- University of New MexicoCollaborator
- University of ChicagoCollaborator
- Vanderbilt UniversityCollaborator
- Children's National Medical CenterCollaborator
- University of Southern CaliforniaCollaborator
- Ohio State UniversityCollaborator
- University of MinnesotaCollaborator
- Hoosier Cancer Research NetworkCollaborator
- University of CincinnatiCollaborator
- Washington University in St. LouisCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.